Item 7.01. Results of Operations and Financial Condition.

On March 8, 2021, Cara Therapeutics, Inc. (the "Company") issued a press release announcing the that the U.S. Food and Drug Administration has accepted and granted Priority Review for the New Drug Application for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits




Exhibit No. Description


  99.1        Press Release dated March 8, 2021
104         Cover page interactive data file (formatted as Inline XBRL)




                                       2

© Edgar Online, source Glimpses